Top 10 Biotech Companies in USA 2026

Biotech used to mean small companies chasing one successful clinical trial result.

Not anymore. In 2025, Amgen alone reported $36.8 billion in total revenue. Gilead’s HIV franchise brought in $20.8 billion. Alnylam, which proved out a once-novel science called RNA interference, grew revenue 65% and turned a profit for the full year. Top US biotech companies now run worldwide sales operations, buy other companies for billions of dollars and set the pace for whole fields of medicine.

They keep evolving, too. In the first half of 2026, Gilead acquired Arcellx, Biogen acquired Apellis and BioMarin acquired Amicus Therapeutics. Abbott completed its acquisition of Exact Sciences. Companies like Celgene and Alexion, which used to make lists like this one, are now part of larger groups.

Also Read: Top 10 Health Insurance Companies in USA 2026

So how did we build this list? We rank by total revenue for fiscal year 2025, as each company disclosed in its full-year results in early 2026. Only independent, publicly traded companies headquartered in the United States whose core business is biotechnology are included. Diversified pharmaceutical giants such as Eli Lilly, AbbVie, Pfizer and Merck are left off; they have a separate article. Where a company has already reported 2026 results, we include that information as well.

Below are the top 10 biotech companies in USA for 2026, what they sell and what to watch next.

Why US Biotech Companies Matter in 2026

American biotech is no longer a side bet for big pharma. Many of the best-selling medicines are now discovered, built and sold by biotech companies.

Biologics drive the biggest franchises

Many top-selling drugs are now biologics such as antibodies. Dupixent, which Regeneron developed with Sanofi, recorded $17.8 billion in global net sales in 2025. Amgen’s Repatha reached $3.0 billion in sales the same year, up 36%.

Rare diseases have become a growth engine

Small patient pools can generate high revenues as well. Vertex makes most of its revenue from cystic fibrosis. Alnylam’s Amvuttra generated $2.31 billion in 2025, and BioMarin’s Voxzogo, which treats achondroplasia, brought in $927 million.

Deals keep reshaping the map

The top biotech companies are also buying other biotech companies. Gilead’s purchase of Arcellx closed in April 2026 for approximately $7.8 billion. Biogen’s acquisition of Apellis Pharmaceuticals, valued at around $5.3 billion, was completed in May 2026. These deals change which companies lead each therapy area.

New modalities are reaching patients

Gene editing, RNA interference and cell therapy are now approved products, not just theory. Vertex has Casgevy on the market, Alnylam has six approved RNAi medicines and Gilead has Kite for cell therapy.

Top 10 Biotech Companies in USA at a Glance

Top 10 Biotech Companies in USA (2026)

Ranked by fiscal 2025 total revenue, with the latest 2026 updates.

1. Amgen

Amgen was started in 1980 in Thousand Oaks, California, under the name Applied Molecular Genetics. It is still based in Thousand Oaks today and has around 31,500 employees. Robert A. Bradway is chairman and CEO. Amgen made total revenues of $36.8 billion in 2025, up 10%, with $35.1 billion from product sales, driven by 13% volume growth.

Newer drugs are driving growth. Repatha was up 36% to $3.0 billion in 2025, Evenity reached $2.1 billion and Tezspire was up 52% to $1.5 billion. Buying Horizon Therapeutics for $27.8 billion, a deal completed in October 2023, added rare disease drugs such as Tepezza and Krystexxa. In August 2026, Amgen reported second-quarter revenue of $10.05 billion and raised its 2026 revenue guidance to $38.2 billion to $39.4 billion. Its obesity candidate MariTide is in the Phase 3 MARITIME program.

Key Biotech Solutions
✔ Cardiovascular care with Repatha
✔ Bone health with Prolia, Xgeva and Evenity
✔ Inflammation and respiratory medicines, including Otezla, Enbrel and Tezspire
✔ Oncology biologics such as Blincyto and Imdelltra

Best for: Anyone tracking the largest and most diversified independent biotech company in the US.

2. Gilead Sciences

Gilead Sciences was founded in 1987 by Michael L. Riordan and is located in Foster City, California. Daniel O’Day is chairman and CEO, and the company has approximately 17,000 employees. Gilead’s total revenues in 2025 were $29.4 billion, up 2%. Its HIV franchise accounted for $20.8 billion, up 6%, and Biktarvy alone generated $14.3 billion.

Gilead now has a drug to prevent HIV, too. Yeztugo, which Gilead calls the world’s first twice-yearly HIV prevention therapy, was approved by the FDA in 2025 and brought in $232 million in the second quarter of 2026. Q2 2026 total revenue was $7.8 billion, up 10%. In oncology, Gilead completed its roughly $7.8 billion acquisition of Arcellx on April 28, 2026. That gives its Kite unit full control of anito-cel, an investigational CAR T-cell therapy for multiple myeloma. Gilead acquired Kite in 2017.

Key Biotech Solutions
✔ HIV treatment led by Biktarvy
✔ Twice-yearly HIV prevention with Yeztugo
✔ Liver disease medicines, including Livdelzi and hepatitis B and D products
✔ Cell therapy for blood cancers through Kite

Best for: Understanding the leader in HIV medicine and a fast-growing cell therapy business.

3. Regeneron Pharmaceuticals

Regeneron Pharmaceuticals was founded in 1988 by Leonard Schleifer, its CEO, and George Yancopoulos, its chief scientific officer. It is located in Tarrytown, New York, and employed about 15,410 people in 2025. Regeneron’s total revenues were $14.3 billion in 2025, up 1%.

Regeneron prides itself on its in-house antibody discovery tools, the VelociSuite technologies, which helped it discover drugs such as Dupixent, Eylea, Praluent and Libtayo. Dupixent, which it sells with Sanofi, reached $17.8 billion in global net sales in 2025, up 26%. U.S. sales of Eylea HD grew 36% to $1.6 billion, while the original Eylea was down 42% to $2.7 billion. Libtayo had global net sales of about $1.5 billion, up 19%. In January 2026, the European Commission approved Eylea 8 mg for retinal vein occlusion.

Key Biotech Solutions
✔ Retinal disease treatments with Eylea HD and Eylea
✔ Type 2 inflammatory disease care through Dupixent
✔ Cancer immunotherapy with Libtayo
✔ Antibody discovery using VelociSuite

Best for: Investors and partners interested in science-led antibody discovery.

4. Vertex Pharmaceuticals

Vertex Pharmaceuticals was founded in 1989 by Joshua Boger and Kevin J. Kinsella. It is headquartered in Boston, Massachusetts, and employs about 6,400 people. Reshma Kewalramani has been president and CEO since April 2020. Vertex reported total revenue of $12.0 billion in 2025, up 9%.

Most of its revenue still comes from cystic fibrosis. Trikafta/Kaftrio accounted for $10.31 billion, and the newer once-daily medicine Alyftrek made $837.8 million. Vertex has begun expanding into other areas. Casgevy, its CRISPR-based gene-editing therapy for sickle cell disease and beta thalassemia, made $115.8 million, and Journavx, a non-opioid pain drug approved in January 2025, made $59.6 million. Vertex expects 2026 revenue of $12.95 billion to $13.1 billion. The FDA has set a target action date of November 30, 2026 for povetacicept in IgA nephropathy.

Key Biotech Solutions
✔ Cystic fibrosis treatments, including Trikafta and Alyftrek
✔ Gene-editing therapy with Casgevy
✔ Non-opioid acute pain relief with Journavx
✔ Kidney disease pipeline led by povetacicept

Best for: Readers who want to follow a rare disease leader moving into new areas.

5. Biogen

Biogen was founded in 1978 in Geneva by a group of scientists that included Walter Gilbert and Phillip Allen Sharp. It is now headquartered in Cambridge, Massachusetts, with Chris Viehbacher as CEO, and has about 7,500 employees. Biogen’s total revenue was $9.89 billion in 2025, up 2%.

Biogen is shifting its mix. Multiple sclerosis revenue was $4.04 billion in 2025, down 7%, while its rare disease portfolio, which includes Spinraza, Skyclarys and Qalsody, grew 8% to $2.15 billion. Biogen also partners with Eisai on Leqembi for Alzheimer’s disease. In May 2026, Biogen completed its acquisition of Apellis Pharmaceuticals, valued at about $5.3 billion. That deal added Syfovre and Empaveli, which together had net product revenue of $689 million in 2025. Biogen expects its 2026 revenue to decline by a mid-single-digit percentage.

Key Biotech Solutions
✔ Multiple sclerosis therapies, including Vumerity and Tysabri
✔ Rare neurological disease care with Spinraza and Skyclarys
✔ Alzheimer’s treatment with Leqembi, through its partnership with Eisai
✔ Eye and kidney disease medicines from Apellis

Best for: Tracking the leader in neuroscience as it moves into new disease areas.

6. Incyte

Incyte was started in 1991 in Palo Alto, California, as a genomics company. Today it is headquartered in Wilmington, Delaware, and Bill Meury has been CEO since 2025. Incyte had total revenue of $5.14 billion in 2025, up 21%, the second-fastest growth on this list.

Jakafi (ruxolitinib) is its main source of revenue. It is used for certain blood cancers and graft-versus-host disease, and it brought in $3.09 billion in 2025, up 11%. Opzelura, a topical cream form of ruxolitinib for dermatology, grew 33% to $678 million. For 2026, Incyte expects total net product revenue of $4.77 billion to $4.94 billion, including $3.22 billion to $3.27 billion from Jakafi. It also sells drugs such as Pemazyre, Monjuvi and Iclusig.

Key Biotech Solutions
✔ Treatment for blood cancers and graft-versus-host disease with Jakafi
✔ Topical treatment for skin conditions with Opzelura
✔ Targeted oncology medicines, including Pemazyre and Monjuvi
✔ Inflammation and dermatology pipeline

Best for: Readers interested in a profitable mid-size biotech company focused on hematology and dermatology.

7. Illumina

Illumina was incorporated in 1998 and is based in San Diego, California. It is the only tools company on this list. Illumina sells the DNA sequencing instruments and reagents that many drug developers, hospitals and research labs use. CEO Jacob Thaysen took over in 2023. Illumina made $4.34 billion in revenue in 2025, flat compared with 2024, while revenue outside China was up 2% to $4.10 billion.

It sells several sequencing platforms. The flagship is the high-throughput NovaSeq X series, which came out in September 2022, alongside the NextSeq, MiSeq and iSeq systems and DRAGEN analysis software. Illumina completed the spin-off of GRAIL in June 2024 after regulators ordered the divestiture. It has since expanded into proteomics by purchasing SomaLogic. Illumina projects 2026 revenue of $4.5 billion to $4.6 billion.

Key Biotech Solutions
✔ High-throughput sequencing with NovaSeq X
✔ Benchtop sequencers, including NextSeq, MiSeq and iSeq
✔ DRAGEN secondary analysis software
✔ Proteomics through SomaLogic

Best for: Labs, hospitals and drug developers that rely on genomic data.

8. Alnylam Pharmaceuticals

Alnylam Pharmaceuticals was founded in 2002 in Cambridge, Massachusetts. It pioneered RNA interference (RNAi) therapies, which silence the genes responsible for disease. It received its first drug approval in 2018 with Onpattro and now has six approved RNAi medicines. Alnylam had total revenues of $3.71 billion in 2025, up 65%, and was profitable on both a GAAP and non-GAAP basis for the full year.

Most of the growth comes from Amvuttra, which treats transthyretin amyloidosis, including the cardiomyopathy form of the disease. Amvuttra sales grew 138% to $2.31 billion in 2025. In Q2 2026, Amvuttra made more than $1 billion in sales, and total revenue was up 67% to $1.29 billion. Alnylam did lower its 2026 net product revenue guidance to $4.7 billion to $5.1 billion, saying demand from second-line patients had normalized. It plans to invest $250 million to expand its manufacturing site in Norton, Massachusetts.

Key Biotech Solutions
✔ Transthyretin amyloidosis treatment with Amvuttra and Onpattro
✔ Rare disease medicines Givlaari and Oxlumo
✔ RNAi drug discovery platform
✔ Royalty and collaboration income from partners

Best for: Anyone following how a new class of medicine grew into a large business.

9. BioMarin Pharmaceutical

BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, California. Its president and CEO is Alexander Hardy. BioMarin makes drugs for rare genetic diseases, and it had total revenues of $3.22 billion in 2025, up 13%.

Voxzogo, which treats achondroplasia, grew 26% to $927 million. BioMarin also sells enzyme therapies such as Vimizim, Naglazyme and Palynziq. It bought Inozyme in July 2025. In 2026 it closed its all-cash acquisition of Amicus Therapeutics for about $4.8 billion, which brings in Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Before Amicus, BioMarin had guided to 2026 revenues of $3.325 billion to $3.425 billion.

Key Biotech Solutions
✔ Achondroplasia treatment with Voxzogo
✔ Enzyme replacement therapies, including Vimizim and Naglazyme
✔ PKU treatment with Palynziq
✔ Fabry and Pompe disease medicines from Amicus

Best for: Patients, partners and investors focused on rare genetic diseases.

10. United Therapeutics

United Therapeutics was founded in 1996 by Martine Rothblatt, who is still its chairperson. It has two headquarters, in Silver Spring, Maryland, and Research Triangle Park, North Carolina. It became a public benefit corporation after a shareholder vote in 2021. United Therapeutics set a record with total revenues of $3.18 billion in 2025, up 11%.

Its focus is pulmonary arterial hypertension. Tyvaso DPI grew 25% to $1.29 billion in 2025, and Orenitram increased 14% to $496.9 million. It also sells Remodulin, Tyvaso and Unituxin, which is used for high-risk neuroblastoma. The company also works on manufactured organs. Its gene-edited pig organs have been used in research transplants, including the UHeart used in the first pig-to-living-human heart transplant in 2022.

Key Biotech Solutions
✔ Inhaled pulmonary hypertension therapy with Tyvaso DPI
✔ Oral and infused treatments, including Orenitram and Remodulin
✔ Pediatric oncology with Unituxin
✔ Xenotransplantation and manufactured organ research

Best for: Readers interested in pulmonary hypertension and the future of organ transplantation.

How to Evaluate Biotech Companies in USA 2026

These are some questions to ask if you’re looking to invest in, work for or partner with biotech companies in USA.

Check the latest SEC filings

Every company listed above files 10-K and 10-Q reports with the SEC. These filings are the most reliable source for revenue, sales of individual drugs and risks. Earnings releases also show whether a company is raising or lowering its guidance.

Look at revenue concentration

One drug can make or break a biotech company. Vertex got most of its 2025 revenue from Trikafta/Kaftrio, and Incyte got roughly 60% of its revenue from Jakafi. Companies such as Amgen, with a wide range of drugs, spread that risk.

Follow the FDA calendar

FDA decisions can change a company’s outlook in a single day. Target action dates, such as Vertex’s November 30, 2026 PDUFA date for povetacicept, are public and worth watching.

Watch for loss of exclusivity

When a drug’s patent expires, biosimilar or generic competitors can enter the market and sales can fall quickly. Check how much of a company’s revenue depends on older drugs and whether newer launches can fill the gap.

Read the deal activity

Look at the acquisitions these companies are making. Gilead’s purchase of Arcellx shows a push into cell therapy. Biogen’s acquisition of Apellis adds eye and kidney disease medicines. BioMarin’s purchase of Amicus gives it a broader rare disease portfolio.

Frequently Asked Questions About Biotech Companies in USA 2026

What is the largest biotech company in the USA?

By fiscal 2025 revenue, Amgen is the biggest independent biotech company in the US, with total revenues of $36.8 billion. Gilead Sciences is second at $29.4 billion.

Why aren’t Eli Lilly, AbbVie or Pfizer on this list?

They are diversified pharmaceutical companies with much broader portfolios, even though they also make biologic drugs. We rank them in our pharmaceutical lists. This list focuses on companies whose main business is biotechnology.

Which US biotech company grew fastest in 2025?

Among the ten, Alnylam Pharmaceuticals grew fastest, with revenue up 65% to $3.71 billion. Incyte followed at 21%.

Which companies just missed the top 10?

Neurocrine Biosciences was just out of reach. It made $2.86 billion in total revenue in 2025 and grew about 21%, so it fell slightly short of United Therapeutics. There isn’t one best biotech company for everyone. The right choice depends on whether you care about scale, growth, a therapy area or a technology platform.

Conclusion

The top 10 biotech companies in USA for 2026 range from Amgen, with nearly $37 billion in annual revenue, to rare disease and RNAi specialists growing at double-digit rates. Some are much bigger than others, but they all have strong science behind them and medicines that patients rely on.

We will keep updating this list of biotech companies in USA as third-quarter 2026 results come in. Upcoming FDA decisions, such as the one on Vertex’s povetacicept, and how well Gilead, Biogen and BioMarin integrate Arcellx, Apellis and Amicus could change the order next year.

Related Reading:

• Top 10 Pharmaceutical Companies in USA 2026
• Top 10 Healthcare Companies in USA 2026
• Top 10 AI Companies in USA 2026